Rodman & Renshaw Downgrades CollaGenex (CGPI) to Market Perform
CGPI Hot Sheet
Rating Summary:1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Rodman & Renshaw downgrades CollaGenex Pharmaceuticals (Nasdaq: CGPI) from Outperform to Market Perform and removes its $19 price target.
The firm said shares of CollaGenex will trade at or around a price of $16.60, which is the tender bid offered by Galderma Pharma yesterday before the market opened.
CollaGenex Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets proprietary medical therapies to the dermatology market.
The firm said shares of CollaGenex will trade at or around a price of $16.60, which is the tender bid offered by Galderma Pharma yesterday before the market opened.
CollaGenex Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets proprietary medical therapies to the dermatology market.
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- Goldman Sachs Downgrades Raytheon (RTN) to Sell; Risk To Back-End Loaded 2012
- KeyBanc Downgrades Lululemon Athletica Inc. (LULU) to Hold; Valuation Call & Slight Concern of U.S. Slowdown
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
